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1 INTRODUCTION 
Tablet is a solid pharmaceutical dosage form containing drug substances with or 
without suitable diluents and prepared by compression or molding method. Drug delivery 
system (DDS) is a strategic tool for expanding markets/indications, extending product life 
cycles and generating opportunities. Oral administration is the most popular route for 
systemic effects due to its ease of ingestion, pain, avoidance, versatility and most 
importantly, patient compliance. Solid oral delivery systems are less expensive to 
manufacture, Patient compliance, high-precision dosing, and manufacturing efficiency 
make tablets the solid dosage form of choice. They do not require sterile conditions. 
Excipients and equipments choices will be significantly affected should solid dosage form 
technologies change in response to the unprecedented shifts in the drug discovery such as 
genomics. 
Injections generally are not favored for use by patients unless facilitated by 
sophisticated auto injectors. Inhalation is one good alternative system to deliver these 
drugs, but the increased research into biopharmaceuticals so far has generate 
predominantly chemical entities with low molecular weights. The developments of 
enhanced oral protein delivery technology by immediate release tablets which may 
release the drugs at an enhanced rate are very promising for the delivery of poorly soluble 
drugs high molecular weight protein and peptide. The oral route remains the perfect route 
for the administration of therapeutic agents because the low cost of therapy, 
manufacturing and ease of administration lead to high levels of patient compliance. 
             Many patients require quick onset of action in particular therapeutic condition 
and consequently immediate release of medicament is required. It is estimated that50% of 
the population is affected by this problem, which results in a high incidence of ineffective 
therapy. 
             The importance of many drug delivery system is to offers a therapeutic amount of 
drug in the particular site in the body to reach promptly and then to maintain the desired 
drug concentration. i.e., the drug delivery system should deliver drug at a rate dedicated 
by the needs of the body over a specified period of treatment. 
 
 
 
 
  
 
1.1 Oral drug delivery 
1, 2
: 
Oral drug delivery is the most widely used route of administration among all the 
routes that have been explored for systemic drug delivery through pharmaceutical 
products of various dosage forms. Oral route is considered most natural, easy to 
administer, uncomplicated, convenient and safe due to its ease of administration, patient 
acceptance and cost effective process. 
For the past centuries, there has been increased demand for patient complaint 
dosage forms. As per result the demand for the technologies has been raised 3 fold 
annually. Since the development cost of new chemical entity is very expensive, the 
pharmaceutical industries are concentrating on the discovering of new drug delivery 
systems for existing drug with an improved efficacy and bioavailability together with 
reduced dosing frequency to minimize the side effects and to release the active drug 
immediately after oral administration to get rapid and complete systemic drug absorption. 
Such IR products result in relatively rapid drug absorption and onset of accompanying 
pharmacodynamic effects. However, after absorption of drug from the dosage form is 
complete, plasma drug concentration rejects according to the drugs pharmacokinetic 
profiles, conventional drug therapy requires periodic doses of therapeutic agents. These 
agents are formulated to perform maximum stability, activity and bioavailability. For 
most drugs, conventional methods of drug administration are effect. 
Oral drug delivery is the most desirable and preferred method of administering 
therapeutic agents for their systemic effects and oral route of drug administration have 
wide acceptance up to 50-60% of total dosage forms. Solid dosage forms are most 
popular because it is ease of administration, accurate dosage form, self-medication, pain 
avoidance and most importantly patient compliance. The most popular solid dosage forms 
are tablets and capsules. But the important disadvantage of these dosage forms is the 
difficulty to swallow 
Oral dosage form is the most widely used route for drug therapy. Over 80% of the 
drugs formulated to produce systemic effects in the United States are produced as oral 
dosage forms. Compared to other oral dosage forms, tablets are the manufacturer’s 
dosage form of choice because of their relatively less expensive of manufacture, package.  
 
 
 
 
  
 
1.2. IMMEDIATE RELEASE DRUG DELIVERY SYSTEM 
3:  
Immediate release drug delivery system is also conventional type of drug delivery 
system and it is defined as – Immediate release tablets are designed to disintegrate and 
release their medicaments with no special rate controlling features such as special 
coatings and other techniques. 
  Tablet must be sufficiently strong and resistant to shock, abrasion, 
 Organoleptic properties are improved by coating of tablet (taste, appearance and 
odour). 
 Tablet should withstand handling during manufacturing, packing, shipping, and use. 
Hardness and friability tests measure this property. 
 It should be uniform in weight and in drug content of the individual tablet. It is 
measured by the weight variation and content uniformity tests. 
  Drug content of the tablet must be bioavailable. This property is measured by the 
dissolution test. Accurate bioavailability can be obtained from the drug levels in the blood 
after its administration. 
 Tablets must be elegant in appearance, characteristic shape, color and other markings 
necessary to identify the product. Tablets must retain all these functional properties which 
include drug stability and efficacy. 
 Large scale manufacturing is feasible in comparison to other dosage forms. Therefore, 
economy can be achieved.       
 Accuracy of dose is maintained since tablet is a solid unit dosage form. 
 Longer expiry period and minimum microbial spillage owing to lower moisture 
content. 
 As tablet is not a sterile dosage form, stringent environmental conditions are not 
required in the tablet department. 
  Packaging (blister or strip) and easy handling over liquid dosage form. 
 Easy to transport in large amount and emergency supplies can be carried by patients. 
 Different types of tablets are available like buccal, floating, colon targeting, 
effervescent, dispersible, soluble, and chewable etc. 
 In comparison to parenterals dosage form, a doctor or a nurse is not required for 
administration.i.e, Self-administration is possible. 
 
 
  
 
Advantages of immediate release drug delivery systems
4  : 
 It releases the drug immediately. 
 More flexibility for adjusting the doses. 
 It can be prepared with minimum dose of drugs. 
 There were no dose dumping problems. 
  Immediate release drug delivery systems can be used in both initial stage and       
             Final stage of disease. 
 At the particular site of action the drug is released from the system. 
 Disadvantages: 
 It is too difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
 Difficult to formulate a drug with poor wettability and slow dissolution into a tablet. 
  It is very slow onset of action as compared to parenterals, liquid orals and capsules. 
 The amount of liquid drug (e.g., vitamin E, simethicone) that can be trapped into a 
tablet is very less amount. 
 Difficult to swallow for children, terminally ill and geriatric patients. 
 Patients undergoing radiotherapy cannot swallow tablet. 
 
                                                                    TABLETS 
“In 1843, the first patent for a hand operated device used to form a tablet was granted.” 
Tablets may be defined as a solid preparations in which containing a single dose of one or 
more active ingredients and obtained by compressing uniform volumes of particles. They 
are intended for oral administration, some are swallowed whole, some after being 
chewed. Some are dissolved or dispersed in water before being administered and some 
are retained in the mouth, where the active ingredient “liberated”.  For the systemic drug 
delivery tablets are mainly used but also for local drug action. Tablets remain popular as a 
dosage form because of the advantages, afforded both to the manufacturer [e.g. simplicity 
and economy of preparation, stability and convenience in packing, shipping and 
dispensing] and the patient [e.g. accuracy of dosage, compactness, portability, blandness 
of taste and ease of administration]. 
Tablets may differ greatly in size and weight depending on the amount of drug substance 
present and the intended method of administration. Although tablets are more frequently 
discoid in shape, they also may be round, oval, oblong, cylindrical or triangular. They 
  
 
may have lines or break-marks and may bear a symbol or other markings. Tablets may be 
coated or non-coated      
Properties of tablets: 
 It should have sufficient strength and resistance to shock and abrasion to with 
stand handling, manufacturing, packing, shipping and use. 
 Tablets must be uniform in weight and in drug content of each tablet.  
 Tablets must be elegant in appearance and must have characteristic shape, colour  
             and other markings necessary to identify the product. 
 Tablet drug content of tablet must be bioavailable. 
 Tablets must retain all these functional attributes, which include drug stability and  
             efficacy. 
 
Advantages of Tablets:  
 Tablets unit dosage form, and they offer the greater capabilities of all oral dosage 
forms for the greatest dose precision and the least content variability. 
 Tablets are the lightest and most compact of all oral dosage forms. 
 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed punch face. 
 Tablet are in general the easiest and cheapest to package and ship of all oral 
dosage forms. 
 They may provide the greatest ease of swallowing with least tendency for “hang-
up” above the stomach. Especially when coated, provided that tablet disintegration is not 
excessively rapid.  
 They lend themselves to certain special release profile products, such as enteric or 
delayed release products.  
 They are better suited to large scale production than other unit oral forms. 
 They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms. 
 One of the major advantages of tablet over capsules is that the tablet is essentially 
“tamperproof dosage form”. 
 
 
 
  
 
Disadvantages of tablets: 
 In some drugs resist compression into dense compacts, owing to their amorphous 
nature/ flocculent/ low density character. 
 Drugs are with poor wetting, slow dissolution properties, optimum absorption 
high in GIT or combination of these features may be difficult or impossible to 
formulate. 
 Bitter tasting drugs, drugs with objectionable odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or a special type of 
coating which may increase the weight of the finished products. 
 Tablet onset of action is slow when compared with parenterals, liquid orals and 
capsules. 
 It is difficult to convert a high dose poorly compressible API in to a tablet of 
suitable size for human use. (Lachman L et al., 1990) 
1.3. TYPES OF TABLETS 
Tablets are classified as follows: 
a) According to the drug release rate from the tablet 
b) According to the method of manufacturing 
c) According to the route of administration or function 
 
According to The Drug Release Rate From The Tablet (USP classification)
4 :
 
      1) Immediate release (conventional) tablets:   
The tablet is intended to be released rapidly after administration or the tablet is dissolved 
and administered as solution. It is the most common type and includes: 
 Disintegrating tablet- e.g. Acetaminophen tablet 
 Chewable tablet         -    e,g. Antacid tablet   
 Sublingual tablet         -      e.g. Vicks menthol tablet 
 Buccal tablet               -            e.g. Vitamin-c tablet 
 Effervescent tablet      -  e.g.  Dispirin tablet (Asprin) 
     
  a) Disintegrating tablets: 
An orally disintegrating tablet or orodispersible tablet (ODT) is a drug dosage 
form available for a limited amount of over-the-counter (OTC and prescription 
  
 
 medications. ODTs differ from traditional tablets in that they are designed to be 
dissolved on the tongue rather than swallowed whole. 
The ODT serves as an alternative dosage form for patients who 
experience dysphagia (difficulty in swallowing) or for where compliance is a known issue 
and therefore an easier dosage form to take ensures that medication is taken.  
Common for all age groups, dysphagia is observed in about 36% of the general 
population, as well as up to 60% of the elderly institutionalized population and 18-22% of 
all patients in long-term care facilities during the last decade, ODTs have become 
available in a variety of therapeutic markets, both OTC and by prescription.  Additional 
reason to use an ODTs is the convenience of a tablet that can be taken without water. 
b) Chewable tablets: 
Sublingual and buccal medications are administered by placing them in the mouth, either 
under the tongue (sublingual) or between the gum and the cheek (buccal). The 
medications dissolve rapidly and are absorbed through the mucous membranes of the 
mouth where they enter into the bloodstream. The medications are compounded in the 
form of small quick-dissolving tablets, sprays, lozenges or liquid suspensions. 
c) Buccal tablets: 
Sublingual and buccal medications are given for a variety of conditions. The most 
common sublingual medication is the nitroglycerin tablet. Its rapid action to relax the 
blood vessels reduces the workload on the heart and relieves the pain of angina pectoris. 
Other buccal and sublingual medications however, serve a variety of purposes-such 
as narcotic pain relief, migraine pain relief, blood pressure control, and mental decline 
due to dementia (i.e., ergoloid) mesylates). This form of medication is extremely 
effective, because it bypasses the digestive system and is absorbed into the bloodstream in 
minutes.  
Not all medications can be prepared for sublingual or buccal administration; some of the 
compounding difficulties are taste, solubility, and dosage limitations of the medicine. 
d) Effervescent tablets:  
Effervescent or carbon tablets are tablets which are designed to break in contact with 
water or another liquid, releasing carbon dioxide in the process. Rapid breakdown often 
may cause the tablet to dissolve into a solution and is also often followed by froth. These 
kinds of tablets are usually used to deliver drugs or to encapsulate cleaning products such 
as the enzymatic cleaners designed for wetsuits. 
  
 
These tablets are products of compression of component ingredients into a dense mass, 
which is packaged in an airtight container or a blister pack. When necessary, people is can 
drop them into water or another liquid to make a solution 
 2) Modified – release tablets: They have release features based on time, course or 
location. They must be swallowed intact.  
 Extended – release tablet:  allowing the reduction in dosing  frequency 
 Delayed - release tablet:  drug release is delayed due to  physiological conditions 
              E.g.:  Enteric coated tablets- the drug is released in the upper part of small 
intestine after which the preparation will pass the stomach. If the drug is sensitive to acid 
or irritant to the stomach lining, an enteric coating can be used. 
 
According to the Method of Manufacturing 
    (a) Compressed tablet- e.g. Paracetamol tablet 
    (b) Molded tablet-       e.g. Nitroglycerin Tablets 
 
According to Their Route of Administration or Function
5
: 
1) Tablets ingested orally  
                These tablets are meant or be swallowed intact along with a sufficient quantity 
of potable water. Exception is chewable tablet. Over 99% of the tablets manufactured 
today are ingested orally. 
 Compressed tablets                -    e.g. Paracetamol tablet 
 Multiple compressed tablets -     e.g. Antacid tablet 
 Multilayered tablets               -    e.g. Ephedrine hydrochloride tablet 
 Sustained action tablets         -     e.g. Verapamil HCl tablet 
 Enteric coated tablets            -      e.g. Asprin tablet 
 Sugar coated tablets              -       e.g. Multi vitamin tablet 
 Film coated table                  -        e.g. Metronidazole tablet 
 Chewable tablets                  -        e.g. Antacid tablet. 
2) Targeted tablet 
             1. Floating tablet-               e.g. Theophylline tablet  
             2. Colon targeting tablet-    e.g. Indomethacin tablet 
 
 
  
 
3) Tablets used in the oral cavity 
                   The tablets under this group are aimed to release API in oral cavity or to 
provide local action in this region. The tablets under this category avoids first-pass 
metabolism, decomposition in gastric environment, nauseatic sensations and gives rapid 
onset of action. The tablets formulated for this region are designed to fit in proper region 
of oral cavity. 
a) Buccal tablets-                          e.g. Vitamin-c tablet 
b) Sublingual tablets-                  e.g. Vicks menthol tablet 
c) Lozenge tablets and trouches- e.g. Clotrimazole tablet 
d)Dental cones 
 
4) Tablets administered by other routes 
       These tablets are administered by other route except for the oral cavity and so the 
drugs are avoided from passing through gastro intestinal tract. These tablets may be 
inserted into other body cavities or directly placed below the skin to be absorbed into 
systemic circulation from the site of application. 
 Implantation tablets, e.g. Adrenaline  
 Vaginal tablets,        e.g. Clotrimazole tablet 
 
5) Tablets used to prepare solutions 
                    The tablets under this category are required to be dissolved first in water or 
other solvents before administration or application. This solution may be for ingestion or 
parenteral application or for topical use depending upon type of medicament used. 
 Effervescent tablets, e.g. Dispirin tablet (Asprin) 
6)  Molded tablets or tablet triturates 
             a)  Dispersing tablets,-   e.g. Enzyme tablet (Digiplex) 
             b)  Hypodermic tablet-, e.g. Morphine Tablet 
Disintegrants are an essential component to tablet formulations. While rapidly 
disintegrating tablets do not necessarily ensure fast bioavailability, slowly  
disintegrating tablets almost always assure slow bioavailability   
 
                        
 
  
 
                     MECHANISM OF TABLET DISINTEGRATION
6, 7 : 
 
The mechanism by which the tablets are broken into small pieces and then 
produce a homogeneous suspension is based on the following steps:                  
-  Capillary action/ water wicking 
-  By swelling 
-  Air expansion /heat of wetting 
-  Due to disintegrating particle/particle repulsive forces 
-  Due to deformation 
-  Due to release of gases 
-  By enzymatic reaction 
 Disintegrants are an essential component to tablet formulations. While rapidly 
disintegrating tablets do not necessarily ensure fast bioavailability, slowly  
disintegrating tablets almost always assure slow bioavailability 
INGREDIENTS TO BE USED FOR ORALLY DISNTEGRATING TABLETS  
Important ingredients that are used in the formulation of ODTs should allow quick 
release of the drug, resulting in faster dissolution. This includes both the actives and the 
excipients. Excipients balance the properties of the actives in FDDTs. This demands a 
thorough understanding of the chemistry of these excipients to prevent interaction with 
the actives. Determining the cost of these ingredients is another issue that needs to be 
addressed by formulators. The role of excipients is important in the formulation of fast-
melting tablets. These inactive food-grade ingredients, when incorporated in the 
formulation, impart the desired organoleptic properties and product efficacy. Excipients 
are general and can be used for a broad range of actives, except some actives that require 
masking agents. 
Binders keep the composition of these fast-melting tablets together during the 
compression stage. The right selection of a binder or combination of binders is essential 
to maintain the integrity and stability of the tablet. The temperature of the excipients 
should be preferably around 30–350C for faster melting properties. Further, its 
incorporation imparts smooth texture and disintegration characteristics to the system. 
Binders can either be liquid, semisolid, solid or mixtures of varying molecular weights 
such as polyethylene glycol. The choice of a binder is critical in a fast- dissolving 
formulation for achieving the desired sensory and melting characteristics, and for the 
  
 
faster release of active ingredients. Commonly available fats such as cocoa butter and 
hydrogenated vegetable oils can also be used. 
 
1.6. SUPER DISINTEGRANTS IN IMMEDIATE RELEASE TABLETS
8-11
: 
A disintegrant is an excipient which is added to a tablet or capsule blend to aid in 
the breakup of the compacted mass when it is put into a fluid environment. This is 
especially important for immediate release products where rapid release of drug substance 
is required. A disintegrant can be added to a powder blend for direct compression or 
encapsulation. It can also be used with products that are wet granulated. While there are 
some tablets fillers (starch, MCC) which aid in disintegration. There are more effective 
agents referred to as super disintegrants.  
A disintegrant is an excipient, which is added to a tablet or capsule blend to aid in the 
breakup of the compacted mass when it is put into a fluid environment.  
ADVANTAGES:  
1. Effective in lower concentrations. 
2. Less effect on compressibility and flowability. 
3. More effective intragranularly. 
Commonly used superdisintegrants are:  
 Sodium Starch Glycolate (Explotab, primogel) used in concentration of 2-8 % 
& optimum is 4%.  
Mechanism of Action: Rapid and extensive swelling with minimal gelling. 
Microcrystalline cellulose (Synonym: Avicel, celex) used in concentration of 2-15% of 
tablet weight. And Water wicking  
Cross linked carboxy methyl cellulose sodium (i.e. Ac-Di-sol) Croscarmellose 
sodium:  
Mechanism of Action: Wicking due to fibrous structure, swelling with minimal gelling. 
Effective Concentrations: 1-3% Direct Compression, 2-4% Wet Granulation. 
 
 
 
 
 
 
 
  
 
TABLE 1:Super disintegrants used in immediate release formulations 
 
 Gas producing disintegrants 
Gas producing disintegrants are used in extra rapid disintegration or readily 
soluble formulation is required. It have also been found the value when poor 
disintegration characteristics have resisted for other methods of improvement. 
Care should be taken during tabletting particularly on moisture level.  
In many instances lower concentration can be used with gas producing 
disintegrants than  required by other disintegrating agents. Certain peroxides that 
release oxygen have been tried but they do not perform as well as those releasing 
carbon dioxide. 
 
 
 
 
 
 
 
 
 
Super 
disintegrants 
Example Mechanism of action Special comment 
Crosscarmellose 
Cross 
linked 
Cellulose 
- Swelling and wicking 
both Swells very little. 
- Swells in two dimensions. 
- Direct compression or 
granulation. 
Sodium starch 
glycolate 
 
Cross 
linked 
Starch 
- Swells 7-12 folds in < 
30 seconds. 
- Swells in three dimensions and 
high level serve as sustain 
release matrix. 
  
 
1.7. TABLET-MANUFACTURING METHODS 
1). Direct compression 
2). Granulation 
 DIRECT COMPRESSION 
12
: 
The term “direct compression” is defined as the process by which tablets are 
compressed directly from powder mixture of API and for suitable excipients. No 
pretreatment of the powder blend by wet or dry granulation procedure is required. 
Manufacturing steps for direct compression 
 Following are the steps involved in the manufacturing of direct compression: 
 Milling of drug and excipients 
 Mixing of drug and excipients 
 Tablet compression 
GRANULATION 
Granulation may be defined as a size enlargement process which converts small 
particles into physically stronger and larger agglomerates. 
Granulation method can be broadly classified into two types:  
(a) Wet granulation 
(b) Dry granulation 
a) Wet Granulation: 
The most widely used process of agglomeration in pharmaceutical industry is wet 
granulation. Wet granulation process simply involves wet massing of the powder blend 
with a granulating liquid, wet sizing and drying 
Important steps involved in the wet granulation 
 Mixing of the drug(s) and excipients 
 Preparation of binder solution  
 Mixing of binder solution with powder mixture to form wet mass 
 Coarse screening of wet mass using a suitable sieve 
  
 
 Drying of moist granules 
 Screening of dry granules through a suitable sieve 
 Mixing of screened granules with disintegrant, glidant, and lubricant 
 
Limitations of wet granulation: 
 The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. Loss of 
material during various stages of processing. 
 Stability may be a major concern for moisture sensitive or thermolabile drugs. 
 Multiple processing steps give complexity and make validation and control 
difficult. 
 An inherent limitation of wet granulation is that any incompatibility between 
formulation components is aggravated. 
b) Dry Granulation 
12
: 
                     In dry granulation process, the powder mixture is compressed without the 
use of heat and solvent. It is the least desirable of all methods of granulation. The two 
basic procedures are to form a compact of material by compression and then to mill the 
compact to obtain granules. There are two methods for dry granulation. The more widely 
used method is slugging, where the powder is compressed and the resulting tablets or 
slugs are milled to yield the granules. The other method is to precompress the powder 
with pressure rolls using a machine such as Chilsonator. 
Steps in dry granulation 
 Milling of drugs and excipients  
 Mixing of milled powders  
 Compression into large, hard tablets to make slugs 
 Screening of slugs 
 Mixing with lubricant and disintegrating agent 
 Tablet compression 
 
  
 
Two main dry granulation processes 
a) Slugging process: Granulation by slugging is the process of compressing dry 
powder of tablet formulation with tablet press having die cavity large enough in 
diameter to fill quickly. The accuracy or condition of slug is not too important. 
Only sufficient pressure to compact the powder into uniform slugs should be 
used. Once slugs are produced they are reduced to appropriate granule size for 
final compression by screening and milling. 
b) Roller compaction: The compaction of powder by means of pressure roll can 
also be accomplished by a machine called chilsonator. Unlike tablet machine, the 
chilsonator turns out a compacted mass in a steady continuous flow. The powder 
is fed down between the rollers from the hopper which contains a spiral auger to 
feed the powder into the compaction zone. Like slugs the aggregates are screened 
or milled for production into granules. (Parikh, Handbook of pharmaceutical 
granulation technology). 
 
Manufacturing defects in tablets: 
Problems involved during the manufacturing of tablets include: 
 Capping  
 Lamination 
 Chipping 
 Sticking  
 Picking 
 Mottling 
 Hardness variation 
 Double impression 
 
  
 
 
 
 
 
  
 
 
 
1.8 Excipients used in tablet formulation: 
   Excipients means any component other then the active pharmaceutical ingredients 
intensionaly added to the formulation of a dosage form. There are many guidelines exist 
to aid in the selection of non toxic excipients such as IIG (inactive ingredient guide). 
GRAS (generally regarded as safe). While selecting excipients for any formulation 
following things should be considered wherever possible. 
Keep the minimum number of excipients, and minimize the quantity of each excipients 
and multifunctional excipients may be given by preference over single functional 
excipients will plays acrucial role in drug delivery system, determining its quality and 
performance. Excipients are normally nontoxic – eg: excipients induced toxicities which 
includes renal failure and death from diethylene glycol, osmotic diarrhoea caused by 
ingested like mannitol, hypersensivity reaction from lanolin and cardiotoxicity induced by 
propylene glycol. 
Super disintegrants : 
Ex:- sodium starch glycolate, croscarmelose, crospovidone. 
Diluents:- 
Ex:- Lactose monohydrate, micro crystalline cellulose, 
Glidents:- 
Ex:- Magnesium stearate, colloidalsillicon dioxide, starch and talc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
DISEASE PROFILE 
 
Hyperlipidemia:
 32, 33, 34
 
Hyperlipidemia is one of the greatest risk factors contributing to prevalence and 
severity of cardiovascular diseases. The term Hyperlipidemia means high Lipid levels 
(lipoprotein) or high Cholesterol levels in the blood.  It is a condition where there will be 
elevations in the levels of plasma total and LDL(Low density lipoprotein) with variable 
changes in HDL(High density lipoprotein).This causes Cardiovascular diseases such as 
atherosclerosis and atherosclerosis associated conditions like Coronary heart 
disease(CHD),Ischemic cerebrovascular disease and Peripheral vascular disease which is 
currently the leading cause of death and illness in developed countries and will soon 
become the pre-eminent health problem worldwide.Dyslipidemias including 
Hyperlipidemia (Hypercholesterolemia)and low levels of High density lipoprotein 
cholesterol(HDL-C) are major causes of increased atherogenesis,both genetic disorders 
and lifestyle(Sedentary behavior and diets high in calories, saturated fat and 
cholesterol)contribute to the dyslipidemias seen in developed countries. The 
epidemiologic data shows that the prevalence of dyslipidemia in Indian adult’s aged 31-
40 age groups is more than in ≤30age group.  High density lipoprotein cholesterol (HDL-
C) was abnormally low in 64.2% males and 33.8% in females. Thus, prevalence of 
dyslipidemia was observed to be higher in males than in females in India. 
                Atherosclerosis, a progressive disease characterized by the accumulation of 
cholesterol, low density lipoprotein-cholesterol (LDL-C) and fibrous elements in the large 
arteries.  Arteries are normally smooth and unobstructed on the inside, as the person ages 
a sticky substance called plaque forms in the walls of your arteries. Plaque is made of 
lipids and other materials circulating in the blood. As more plaque builds up, arteries 
narrow stiffen and plaque rupture occurs and thus enough plaque may build up to reduce 
blood flow through arteries.
 
 Plaque rupture leads to platelet activation and thrombosis 
which leads to blood clots. This increases the risk of heart disease, stroke and other 
vascular diseases. Thus atherosclerosis constitutes the single most important contributor 
to this growing burden of cardiovascular disease. World health organization (WHO) 
reports that high blood cholesterol contributes to approximately 56% of cases of 
cardiovascular diseases worldwide and causes about 4.4million deaths each year.
 
  
 
 
 
Lipoproteins: 
Lipids (fat-soluble molecules) are transported in a protein capsule. The size of that 
capsule determines its density.  Lipoproteins are macromolecular assemblies that contain 
proteins and lipids, including free and esterified cholesterol, triglycerides, and 
phospholipids. The protein components known as apolipoproteins, provide structural 
stability to the lipoproteins, and also may function as ligands in lipoprotein–receptor 
interactions or as cofactors in enzymatic processes that regulate lipoprotein metabolism. 
In all lipoproteins, the most water-insoluble lipids (cholesteryl esters and triglycerides) 
are core components, and the more polar water-soluble components (apoproteins, 
phospholipids and unesterified cholesterol) are located on the surface. The lipoproteins 
have been divided into classes on the basis of their particle size and density. They also 
differ in the nature of apoproteins, the ratio of TG and CHE, tissue of origin and fate.
 
 
 
Classification: 
        The major class of lipoproteins and their properties are presented and describes 
apoproteins that have well-defined roles in plasma lipoprotein metabolism. Five major 
lipoproteins exist, each with a different function:  
 Chylomicrons 
 Very–low-density lipoproteins (VLDLs) 
 Intermediate-density lipoproteins (IDLs) 
 Low density lipoproteins(LDLs) and  
 High density lipoproteins(HDLs)   
    The protein components of the lipoprotein are known as apolipoproteins or 
apoproteins. The different apolipoproteins serve as cofactors for enzymes, and ligands for 
receptors. 
  
 
Pathways of Lipid Metabolism: 
          Each class of lipoprotein has a specific role in lipid transport. Three main pathways 
are responsible for the generation and transport of lipids within the body: 
 Exogenous pathway 
  
 
 Endogenous pathway 
 
Exogenous  pathway:  
 Cholesterol and triglycerides(CHO + TG) are  absorbed from the GIT are 
transported in the lymph and than  in the plasma as Chylomicrons to capillaries in 
muscle and adipose tissues. Here the core triglycerides are hydrolysed by 
lipoprotein lipase, and the tissues take up the resulting  free fatty acids. 
 Cholesterol  is liberated within the liver cells and may be stored, oxidised to bile 
acids or secreted in the bile unaltered. Alternatively it may enter the endogenous 
pathway of lipid transport in VLDL. 
 
 Endogenous  pathway: 
 Cholesterol and newly synthetised Triglycerides(TG‘s) are transported from the 
liver as Very low density lipoprotein( VLDL) to muscle and adipose tissue, there 
TG are hydrolysed and the resulting fatty acids enter the tissues 
 The lipoprotein particles become smaller and ultimetaly become LDL , which 
provides the source of CHO for incorporation into cell membranes, for synthesis 
of steroids, and bile acids.  Cells take up LDL by endocytosis via LDL receptors 
that recognise LDL apolipoproteins . 
 Cholesterol can return to plasma from the tissues in HDL particles and the 
resulting cholesteryl esters are subsequently transferred to VLDL or LDL  
 One particular subtype of LDL  is associated with atherosclerosis (localised in 
atherosclerotic lesions). LDL can also activate platelets, constituting a further 
thrombogenic effect. 
 
 
 
 
 
 
  
 
 
                               FIG: 1 LIPOPROTEIN METABOLISM 
 
Causes: 
Hyperlipidemia also known as hyperlipoproteinemia or hyperlipidaemia (British English) 
is divided into two sub-types. They are: 
 Primary hyperlipidemia is usually due to genetic causes (such as a mutation in a 
receptor     protein) 
 Secondary hyperlipidemia arises due to other underlying causes such as diabetes.  
The most common causes of acquired hyperlipidemia are: 
 Diabetes mellitus 
 Use of drugs such as diuretics, beta blockers, and estrogens 
Other conditions leading to acquired hyperlipidemia include: 
 Hypothyroidism 
 Renal failure 
 Nephrotic syndrome 
 Alcohol usage 
 Some rare endocrine disorders and metabolic disorders 
Treatment: 
  
 
        Many drugs have come in market as anti-hyperlipidemic drugs also known as 
hypolipidemic drugs. Diverse group of pharmaceuticals are used in the treatment of 
hyperlipidemias. They are called lipid-lowering drugs (LLD) or agents. These are the 
drugs which lower the levels of lipids and lipoproteins in blood.
  
  The main agents used clinically as hypolipidaemic drugs are: 
 HMG-CoA reductase inhibitors(Statins) 
 Bile acid sequestrants(Resins) 
 Fibric acid derivatives 
 Nicotinic acid(Niacin) 
 Other Hypolipidaemics. 
         Antihyperlipidemic drugs decrease cholesterol and triglyceride levels in several 
ways. Although the end result is a lower lipid blood level, each has a slightly different 
action. 
Atorvastatin calcium: 
         Atrovostatin is drug which is classified under HMG-CoA reductase inhibitors also 
called as statins. This drug appears to have one of two activities, namely 
 Inhibiting the manufacture of cholesterol or 
 Promoting the breakdown of cholesterol. Different statins differ in their potency 
and maximal efficacy in reducing LDL-CH levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
2 REVIEW OF LITERATURE 
Patel Dipika, et al (2012)
16   
 Formulation, development and evaluation of immediate 
release tablets containing atorvastatin calcium drug was studied by Patel Dipika, Patel 
Vijayakumar
16
 to develop amorphous form of Atorvastatin Calcium into immediate 
release tablets. Pre-formulation studies and drug excipients compatibility studies  was 
done initially and the results obtained were directs the way and method of formulation. 
Preformulation and drug excipient compatibility study, prototype formulation carried out 
for the highest dose of Atorvastatin (80 mg) and optimized to get the final formula. All 
the mentioned batches were done by wet granulation method. Granules were evaluated for 
tests such as loss on drying (LOD), preformulation studies such as bulk density, tapped 
density, compressibility index and Hauser’s ratio and sieve analysis before compression. 
Tablets were tested for weight variation, thickness, hardness, friability and dissolution. In 
vitro dissolution studies were performed and  f1 andf2 values were calculated. Dissolution 
profile of F8 was matched perfectly with marketed (innovator) formulation and f2 value 
was found to be excellent. Also the impurity profile and stability result of F8 was found to 
be excellent. It can be concluded that the immediate release tablet was beneficial for 
delivering the drug which needs faster release to achieve the immediate action. 
Sachin v. Wankhede, 
 
et al (2012)
17 
Formulation and stabilization of atorvastatin tablets 
by Sachin v. Wankhede, S.Y.Manjunath,  Subal Debnath
, 
 was planned to develop 
Atorvastatin calcium amorphous into immediate release tablets.Pre-formulation study and 
drug excipients compatibility study was done initially and the results obtained were 
directs the way and method of formulation. Preformulation and drug excipient 
compatibility study,prototype formulation carried out for the highest dose of Atorvastatin 
calcium (80 mg) and optimized to get the final formula. Atorvastatin calcium 
(amorphous) is highly susceptible to hydrolysis and oxidation. So wet granulation method 
was avoided. All the mentioned batches were done by dry granulation method by roller 
compaction. Granules were evaluated for tests such as loss on drying (LOD), 
preformulation studies such as bulk density, tapped density, compressibility index and 
Hauser’s ratio and sieve analysis before compression.  weight variation of the tablet were 
tested, thickness, hardness, friability and dissolution. In vitro dissolution studies were 
performed and Formulation 1 (F1) and Formulation 2 (F2) values were calculated. 
Dissolution profile ofF5 was matched perfectly with marketed (innovator) formulation 
and F2 value was found to be excellent, also the impurity profile and stability result of F5 
  
 
was found to be excellent. It can be concluded that the immediate release tablet was 
beneficial for delivering the drug which needs faster release to achieve the immediate 
action. 
Subhadeep Chowdhury, Subhabrotamajumdar et al (2010)
18
 Statistical optimization 
of fixed dose combination of Glimepiride and Atorvastatin calcium in immediate release 
tablet formulation was studied and long term administration of oral hypoglycemic drugs 
has been reported to be associated with increased cardiovascular mortality as compared to 
treatmentwith diet alone or diet with insulin. For this complication atorvastatincalcium 
can be used to reduce the cardiovascular mortility. The objective of the present study was 
to evaluate the effects of two factors (amount of carboxymethylcellulose sodium and 
sodium starch glycolate) on drug release of atorvastatin calcium and glimepiride from the 
tablet in order to optimize the formulation by 2 factor 3 level factorial design. 
Twoindependent variables taken were carboxymethylcellulose sodium (10mg, 12.5mg 
and 15 mg)and sodium starch glycolate (2.5 mg, 5mg and 7.5mg). The evaluated response 
were percentage release of atorvastatin calcium in 60 min (Y1) and percentage release of 
glimepiride in 60 min (Y2) was taken as the response variables.Drug release was 
measured in USP 2 (paddle type) apparatus using 900 ml 0.05 M phosphate buffer(pH6.8) 
solution at a rotation speed 75 rpm. The dissolution data revealed that amount of 
carboxymethylcellulose sodium and sodium starch glycolate are very important to 
achieve optimum formulation. Using responses and resulted statistical equations, 
optimum formulation was predicted. It shows that sodium starch glycolate has more effect 
than carboxymethylcellulose sodium on the tablet formulation and formulation with 14.78 
mg of carboxymethylcellulose sodium and 7.5 mg of sodium starch glycolate is the 
optimized formulation. The optimized formulation produced dissolution profiles that were 
closed to predicted values. 
M.Manikandan, K Kannan, Sthirumurugu, R.Manavalan et al
19
Design and 
evaluation of amlodipine besilate and atorvastatin calcium tablets was studied
 
by 
M.Manikandan, K Kannan, Sthirumurugu, R.Manavalan.
 
Amlodipine besilate is a 
calcium channel blockers used for the treating high blood pressure, certain types of 
angina and coronary heart failure. Atorvastatin calcium known as Statins is used for 
lowering blood cholesterol and in the treatment of primary hypercholesterolemia and 
dyslipidemia. The objective of the present investigation was to formulate and evaluate an 
oral administrable tablet containing Amlodipine besilate and Atorvastatin calcium by wet 
granulation method. The tablets were prepared using Microcrystalline cellulose, Calcium 
  
 
carbonate, polysorbate 80, Hydroxypropyl cellulose, Pregelatinized starch, 
Croscarmellose sodium, Colloidal anhydrous silica and Magnesium stearate. 
Preformulation studies were performed prior to compression. The prepared tablets were 
evaluated for various pre-compression characteristics like angle of repose, bulk density, 
tapped density, cars index and hausner’s ratio, loss on drying and post-compression 
characteristics like Appearance, Weight variation, Hardness, Thickness, Disintegration, 
Friability, In vitro Dissolution studies. The stability studies were carried out for the 
optimized batch for three months and it showed no significant changes in the 
physicochemical parameters and in vitro release pattern. The present study concludes that 
combined pill has the potential to improve the management of hypertensive patients with 
additional cardiovascular risk factors, especially dyslipidemia by reducing pill burden and 
prescription costs 
V.Mallikarjun, P.Rajasridharrao et al
20 
Formulation and evaluation of bilayer tablets 
of atorvastatin and nicotinic acid in different media by was aimed to formulate and 
evaluate the bilayer tablets using different media, toknow the release studies in which 
media the release of the drug is in controlled manner. The bilayer tablets of Atorvastatin 
(AT) calcium and Nicotinic acid (NA) were prepared to give Atorvastatin asimmediate 
release and controlled release of Nicotinic acid. Bi-Layer tablets consists of two layers 
i.e.,immediate release layer containing of disintegrants like croscarmellose sodium and 
Cross-Povidone and controlled release layer containing HPMCK100M as retard layer. 
Combination of Atorvastatin andnicotinic acid is accepted to bring down cholesterol 
levels. Three different formulations were prepared bywet granulation method which 
consists of various disintegrants and polymer in different ratios namelyATNA1, ATNA2 
and ATNA3.The tablets were evaluated for various parameters like weight variation, 
thickness, hardness andfriability. The release studies were carried out using different 
media i.e. buffer PH 7.4, 6.8, 4.5 and 0.1N HCl using USP dissolution testing apparatus II 
(paddle type) for 12hrs.The controlled release layer of Nicotinic acid formulation 
containing HPMC K100 shows optimized drug in 0.1N HCl within 12 hours.Thelayer of 
atorvastatin containing Cross-Povidone shown satisfactory release from dosage 
forms.Hence, from the above study we conclude that ATNA2 has shown good release in 
0.1N HCl compared to other media with different ratios of polymers. 
S.Brito raj et al (2011)
21 
Inlay tablet of atorvastatin calcium with sustained release 
metoprolol tartarate   was designed a dual retard technique of once daily Inlay tablet of 
Atorvastatin calcium as Immediate Release (IR) formulation with Matrix tablet of 
  
 
Metoprololtartarate as Sustained release (SR) formulation for Hypertension and 
Atherosclerosis. The Inlay tablet was prepared by Wet granulation method. The 
Compatibility of the drug with various excipients was studied by Differential scanning 
calorimetry (DSC). The formulations were developed by using polymers like Guar gum, 
Eudragit, HPMC for sustained release layer and Sodium starch glycolate, Cross povidone, 
Cross carmellose sodium as Super disintegrants for immediate release layer. Six 
formulations (F1-F6) were prepared and evaluated for various parameters like Thickness, 
Hardness, Weight variation, Disintegration, Swelling Erosion behavior, Simultaneous 
analysis by both UV and HPLC, In vitro  release and Stability studies at 40º±2ºC, RH 
70±5%. Among the six formulations (F1-F6), F4 possess expected release pattern in both 
immediate release layer and sustained release layer. Further from the Release kinetics it 
was revealed that the drug release for formulation F4 follows Zero order. Thus the study 
concludes that the formulation can overcome the disadvantages of other multilayered 
tablets and can be used to treat the patients having high blood pressure with 
Hyperlipidemia that plays major risk factors for CHD. 
Min-soo kim et al(2008)
22
 Preparation, characterization and in vivo evaluation of 
amorphous atorvastatin calcium nanoparticles using supercritical anti solvent (sas) 
process by Min-soo kim was studied to deal with amorphous atorvastatin calcium 
nanoparticles were successfully prepared using the supercritical antisolvent (SAS) 
process. The eﬀect of process variables on particle size and distribution of atorvastatin 
calcium during particle formation was investigated.Solid state characterization, solubility, 
intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were 
performed. Spherical particles with mean particle size ranging between 152 and 863 nm 
were obtained by varying process parameters suchas precipitation vessel pressure and 
temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, 
TGA,FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium 
existed as anhydrous amorphous form and no degradation occurred after SAS process. 
When compared with crystalline form (unprocessed drug), amorphous atorvastatin 
calcium nanoparticles were of better performance in solubility and intrinsic dissolution 
rate, resulting in higher solubility and faster dissolution rate. Inaddition, intrinsic 
dissolution rate showed a good correlation with the solubility. The dissolution rates of 
amorphous atorvastatincalcium nanoparticles were highly increased in comparison with 
unprocessed drug by the enhancement of intrinsic dissolution rateand the reduction of 
  
 
particle size resulting in an increased speciﬁc surface area. The absorption of atorvastatin 
calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats 
was markedly increased. 
Ankushchoudhary et al (2012)
23 
Development and characterization of an atorvastatin 
solid dispersion formulation using skimmed milk for improved oral bioavailability was 
done by ankushchoudhary to deal with Atorvastatin has low aqueous solubility resulting 
in low oral bioavailability (12%) and thus presents a challenge in formulating a suitable 
dosage form. To improve the aqueous solubility, a solid dispersion formulation of 
atorvastatin was prepared by lyophilization utilizing skimmed milk as a carrier. Six 
different formulations were prepared with varying ratios of drug and carrier and the 
corresponding physical mixtures were also prepared. The formation of a solid dispersion 
formulation was conﬁrmed by differential scanning calorimetry and X-ray diffraction 
studies. The optimum drugto-carrier ratio of 1:9 enhanced solubility nearly 33-fold as 
compared to pure drug. In vitro drug release studies exhibited a cumulative release of 
83.69% as compared to 22.7% for the pure drug. Additionally, scanning electron 
microscopy studies suggested the conversion of crystalline atorvastatin to an amorphous 
form. In a Triton-induced hyperlipidemia model, a 3-fold increase in the lipid lowering 
potential was obtained with the reformulated drug as compared to pure drug. These 
results suggest that solid dispersion of atorvastatin using skimmed milk as carrier is a 
promising approach for oral delivery of atorvastatin. 
Kirti Rode et al (2012)
24
 Study on formulation development and evaluation of 
atorvastatin calcium film coated tablet  with the “formulation and evaluation of 
atorvastatin calcium tablets 80mg” (Antihypercholesterolemic and antihyperlipidemic) by 
wet granulation technique.Various Formulation of Film coated (PEG 6000 & HPMC are 
film former) Tablets of Atorvastatin calcium were prepared by using different proportion 
& combination of excipients.All the physical parameters of all batches (ACT 01-ACT 05) 
were determined from which ACT 05 batch was found to comply with the standard due to 
its maximum amount of drug release.Formulation ACT 05 was formulated as film coated 
tablets by using PEG 6000 as a Plasticizer and HPMC as a Polymer. ACT 05 shows best 
dissolution profile when compared to marketed drug which shown 114.89% drug release 
after 30 mins. 
Furquannazimuddin khan et al (2012)
25 
Enhanced bioavailability and dissolution of 
atorvastatin calcium from floating microcapsules using minimum additives  deals with 
atorvastatin calcium, a lipid-lowering drug, is much less bioavailable because of reduced 
  
 
solubility in acidic media.  Multiple-unit floating microcapsules of Atorvastatin calcium 
(ATC) were developed to expand the gastric residence time of the drug, as ATC has 
maximum rate of absorption in the upper GI tract. Floating microcapsules were prepared 
by Emulsion-solvent evaporation technique through incorporation of dioctyl sodium 
sulphosuccinate (DSS) as a dissolution enhancer. The microcapsules were assessed for 
shape, size, drug entrapment efficiency, stability and in-vitro drug dissolution rate and 
were subjected to SEM, DSC and PXRD studies. The ATC-loaded floating microcapsules 
were spherical in shape and had the particle size of about 28.10 µm and drug-loading 
efficiency of  about 96.55 %. The floating microspheres containing DSS had significantly 
higher drug dissolution rates than those without DSS. The best formulation, AT4, 
consisting of Ethyl cellulose, DSS and Poly Ox®, had a maximum drug dissolution rate 
of 97.86 %, as compared to Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate 
of only 54% during a period of 12 h in acidic media. A pharmacokinetic study performed 
on albino rabbits illustrates that the bioavailability of AT4 floating microcapsules 
significantly increased to nearly 1.7 times that of Storvas 80 mg. The present study 
indicates that the use of multi-unit floating microcapsules for delivery of ATC can 
improve its bioavailability. 
N.Arunkumar et al (2010)
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Formulation development and in vitro evaluation of 
nanosuspensions loaded with atorvastatin calciumby N.Arunkumar
 
is aimed to prepare 
and characterize nanosuspensions of a poorly soluble drug (Atorvastatin calcium) in order 
to enhance its solubility and dissolution characteristics. Nanosuspensions were prepared 
by high pressure homogenization technique. They were characterized by thermal 
gravimetric analysis (TGA), differential scanning calorimetry (DSC), powder X-ray 
diffraction (PXRD), solubility, andin vitro drug release studies. The absence of 
atorvastatin peaks in PXRD profiles of nanosuspensions suggests the transformation of 
crystalline drug into an amorphous form. TGA examination suggested that the drug was 
converted into anhydrous form from the original trihydrate form. DSC curves also 
compliment the result obtained by TGA and PXRD. The effect of particle size was found 
to be significant on the saturation solubility of the drug. The in vitro drug release studies 
showed a significant increase in the dissolution rate of nanosuspensions as compared with 
pure drug. This study has shown that initial crystalline state is reduced following particle 
size reduction and that the dissolution characteristics of atorvastatin nanosuspensions 
were significantly increased in regards to the pure drug. Being simple metscaled up, this 
approach should have a general applicability to many poorly water-soluble drug entities.
 
  
 
 
                                       3. AIM AND OBJECTIVE 
 
AIM OF THE STUDY 
To Formulate and evaluate of Atorvastatin calcium immediate release tablets using super 
disintegrants 
OBJECTIVE OF THE STUDY 
The present study is planned with the following objectives: 
1. To carry out preformulation studies on pure drug and precompressional 
characterization of complex. 
2. To prepare immediate release Atorvastatin Calcium tablets with different super 
disintegrants by using wet granulation method. 
3. To investigate the drug-polymer interactions. 
4. To evaluate the prepared tablets with respect to various physicochemical 
parameters like weight variation, hardness, friability, thickness, in vitro 
disintegration and dissolution time. 
5. To carry out stability studies for selected formulations as per ICH guidelines 
6. Comparison with marketed product. 
 
 
  
 
 
 
                             
                                     
                           
 
 
 
 
 
  
 
4. PLAN OF WORK 
 
With the above mentioned aims and objectives, the work is planned as follows 
1. Literature review 
2. Preparation of granules by wet granulation method 
3. Pre compression studies  
 Bulk density 
 Tapped density 
 Compressibility index 
 Angle of repose 
 Moisture content 
 Sieve analysis 
4. Compression of granules into tablets                          
5. Evaluation of prepared tablets 
 Appearance 
 Hardness 
 Weight variation test 
 Friability 
 Thickness 
 Disintegration 
 Dissolution  
 Stability studies  
6. Selection of best formulation on the basis of Invitro drug release 
 
 
 
 
 
 
 
 
 
 
  
 
4.1 PRE-FORMULATION STUDIES 
Preformulation testing is the first step in the rational development of dosage forms of a 
drug. It can be defined as an investigation of physical and chemical properties of drug 
substance, alone and when combined with excipients. A complete evaluation of 
physicochemical properties may provide a rationale for designing the formulation or 
support the need for molecular modification or merely confirm that there are no 
significant barriers to the compound development. 
Angle of Repose 
 The angle of repose was measured by passing the prepared granules through a 
sintered glass funnel of internal diameter 27 mm on the horizontal surface. The height (h) 
of the heap formed was measured with a cathetometer, and the radius (r) of the cone base 
was also determined. Results are shown in Table 12. The angle of repose (Ɵ) was 
calculated from equation
 
Angle of repose (Ɵ) = tan-1h/r 
Table:2 Relationship between angle of repose and flow properties: 
Angle of repose (Ɵ) degree Flow 
<25 Excellent 
25 – 30 Good 
30 – 40 Passable 
>40 Very poor 
 
Bulk density
 
The term bulk density refers to a measure used to describe a packing of particles. It is 
expressed in gm/ml and was determined using a balance and measuring cylinder. Initially 
the weight of the measuring cylinder was tarred. Then, 4 gm presieved (40#) bulk drug 
were poured into the measuring cylinder using a funnel and weighed (M). Then volume of 
the powder (Vb) was taken. Results are shown in Table 12. Bulk density of the granules 
was calculated using following formula.        
 Bulk density = M/Vb 
 
 
 
 
  
 
Tapped density 
 Blend was tapped for a fixed number of taps. The minimum volume (Vt) occupied 
in the cylinder and the weight (M) of the blend was measured. Results are shown in Table 
12. The tapped density was calculated using following formula. 
Tapped density = M/ Vt 
Compressibility (Carr’s) Index 
An accurate weight of granules was poured into a volumetric cylinder to occupy a volume 
(V0) and then subjected to a standard tapping procedure onto a solid surface until a 
constant volume was achieved (Vf). Results are shown in Table 12.The Carr’s index was 
calculated using equation 
Compressiblity index = 100 × V0 - Vf 
               V0 
 
Table3: Grading of powders for their flow properties according to carr’s index:  
 
Carr’s index % Flow 
5 – 15 Excellent 
12 – 16 Good 
18 – 21 Fair to Passable 
23 – 35 Poor 
33 – 38 Very Poor 
>40 Very very Poor 
 
Hausner ratio
 
Hausner’s ratio is an indirect index of ease of powder flow. Results are shown in Table 
12. It is calculated by the following formula,  
Hausner’s ratio = tapped density / bulk density 
Lower Hausner’s ratio (<1.25) indicates better flow properties than higher ones (>1.25). 
 
 
 
HYGROSCOPICITY: 
  
 
    Weigh the glass vessel of 50mm in external diameter and 15mm height along with the 
stopper (m1), place the amount of substance prescribed for the test of loss on drying in the 
vessel and weigh(m2).Place the unstopped vessel in a desiccator to 25 degree 
Celsius,80% RH an allow it to stand for 24 hrs. Stopper the weighing vessel and weigh 
(m3). Calculate the % increase in mass using the following equation 
                             Weight gain= (m3-m2)/(m2-m1)* 100 
 
Table: 4  Hygroscopicity 
HYGROSCOPICITY WEIGHT GAIN(W/W) 
Slightly hygroscopic 0-0.12% 
Hygroscopic 0-12.2% 
Very hygroscopic 2-15% 
Deliquescent >15% 
 
Drug Excipient Compatibility studies: 
The compatibility of drug and formulation components is important prerequisite before 
formulation. It is therefore necessary to confirm that the drug does not react with the 
polymers and excipients under experimental conditions and affect the shelf life of product 
or any other unwanted effects on the formulation. 
Procedure: 
Drug is mixed with excipients in different ratio. These mixtures were kept in a 5ml glass 
white colored vials and packed properly. These vials are exposed to 1) room temperature 
2)2 – 8° C and 3) 40˚c / 75%RH. 15gm of blend is prepared which is filled in 3 vials. 
Observations for physical appearance are made at zero weeks, 2 week, and 4week, the 
samples were withdrawn for analysis of following parameter: 
1. Moisture content 
2. Assay 
3. Related substance 
4. Appearance. 
 
 
 
  
 
  4.2 FORMULATION STUDIES 
Atorvastatin Calcium (Pure Drug) 
       By using spectrophotometry Atorvastatin calcium can be estimated. In the present 
study UV spectrophotometry was used for estimation of the Atorvastatin calcium. 
Estimation of Atorvastatin calcium by UV method in methanol 
         A simple, fast, reproducible and precise method of estimation for Atorvastatin 
calcium was carried out based on the solubility of Atorvastatin calcium in methanol. 10 
μg/ml solution was scanned from 200-400 nm. The absorption maximum was found to be 
244 nm. Beers range was found to be 5-25μg/ml. 
Preparation of stock solution: 
         Preparation of the stock solution was made by taking 100 mg of atorvastatin 
calcium was dissolved in 100 ml of methanol to get a 1 mg/ml solution. 
Preparation of working standard solution 
         10 ml (1000 μg/ml) of stock solution was diluted to 100 ml with methanol to get 
100μg/ml solutions. From above mentioned working standard solution, aliquots of 0.5-
7.5ml is taken and then diluted up to 25 ml with methanol to get 2-30 μg/ml respectively. 
The absorbance of the solutions was read at 244nm. Absorbance was plotted against 
respective concentration to obtain standard graph. 
Estimation of Atorvastatin calcium by UV method in FaSSIF 
Preparation of fasted state simulated gastric fluid (FaSSIF, pH 6.5) 
Sodium dihydrogen phosphate: 3.438 gm 
Sodium chloride  : 6.186 gm 
Sodium hydroxide  : 0.348 gm 
Deionised water qs  : 1 liter 
A simple, fast, reproducible and precise method of estimation for Atorvastatin calcium 
was carried out based on the solubility of Atorvastatin calcium in fasted state simulated 
intestinal fluid. 10 μg/ml solution was scanned from 200-400 nm. The absorption 
maximum was found to be 244nm. Beers range was found to be 5-25μg/ml. 
Preparation of stock solution 
10 mg of atorvastatin calcium was dissolved in 100 ml of fasted state simulated intestinal 
fluid and sonicated to get 100 μg/ml solution. 
Preparation of working standard solution 
40 ml (100μg/ml) of stock solution was diluted to the 100 ml with fasted state simulated 
intestinal fluid to get a 40 μg/ml solutions. From the standard solution, aliquots of 0.5-
  
 
6.5ml is taken and is diluted up to 10 ml with fasted state simulated gastric fluid to get 5-
25μg/ml respectively. The absorbance of the solutions was observed at 244nm. 
 To obtain standard graph.absorbance was plotted against the respective concentration 
 
Table 5: Standard calibration curve of Atorvastatin Calcium 
S.no Concentration 
(mcg/ml) 
Absorbance 
1 0 0 
2 2 0.142 
3 10 0.283 
4 15 0.434 
5 20 0.565 
6 25 0.686 
 
Figure 2: Calibration curve of Atorvastatin calcium                                                               
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4.3 EVALUATION STUDIES 
Hardness
 
The tablet hardness, which is the force required to break a tablet in a diametric 
compression force. The hardness tester used in the study was Monsanto hardness tester, 
which applies force to the tablet diametrically with the help of an inbuilt spring. It is 
expressed in KP.  
Thickness 
Thickness of the tablets are measured by using Vernier calipers, it is expressed in mm. 
Friability 
Friability of the tablets was determined using Roche friability (Electrolab, Mumbai). This 
device subjects the tablets to the combined effect of abrasions and shock in a plastic 
chamber revolving at 25 rpm and dropping the tablets at a height of 6 inches in each 
revolution. Pre-weighed sample of tablets was placed in the Friabilator and were 
subjected to 100 revolutions. Tablets were de dusted using a soft muslin cloth and 
reweighed. 
The friability (f) is given by the formula. 
f = (1- W0 / W) × 100  
Where, W0 is weight of the tablets before the test and  
           W is the weight of the tablet after the test 
Weight variation test 
 Weight variation test was carried out as per IP. Twenty tablets were randomly selected 
and individually weighed. The average weight and standard deviation was calculated. 
In vitro disintegration time 
The disintegration time of the tablet was measured in water (37±2°C) according to 
disintegration test apparatus with disk. The time in seconds taken for the complete 
disintegration of the tablet with no palpable mass in the apparatus was measured in 
seconds. Three tablets from each batch (formulation) were tested for the disintegration 
time calculations.  
 
In vitro drug release studies: 
The immediate release tablets are subjected to in vitro drug release studies in pH 6.8 
Phosphate buffer for 30 minutes to access the ability of the formulation for providing 
immediate drug delivery. Drug release studies were carried out in eight stage dissolution 
test apparatus using specified volume of dissolution media maintained at 37±10C. The 
  
 
tablets are kept in the cylindrical basket and rotated at 100 rpm 10ml of the sample from 
the dissolution medium are withdrawn at each time interval (5,10,15&30 minutes) and 
5ml of fresh medium was replaced each time. The sample was filtered and from the 
filtrate was taken.  
DISSOLUTION STUDY: 
                Medium          : 6.8 Phosphate Buffer  
                          Type of apparatus                       : USP -   II (paddle type) 
                RPM               : 100 
                Volume             : 900ml 
                Temperature              : 37ºC± 0.5 
                Time                : 30min  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
5. DRUG PROFILE 
 
ATORVASTATIN CALCIUM
27, 28. 
 
Chemical Name: [R-(R*, R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-
phenyl-4-[(phenyl amino) carbonyl]-1Hpyrrole-1-heptanoic acid. 
 
 
Molecular Weight:      Chemical Formula: 
1209.42       (C33H34FN2O5)2Ca•3H2O 
 
Chemical Structure: 
 
          
 
Description      :  White to off-white crystalline powder. 
 
Solubility        : Insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium  
is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; 
slightly soluble in ethanol; and freely soluble in methanol. 
 
Category        : Antihyperlipidemic 
 
Storage           : Store in a well closed container and protected from light. 
 
Dose                : Administered in doses 10, 20, 40 and 80 mg. 
 
 
 
  
 
Mechanism of action:  
 As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA 
reductase. Unlike most others, however, it is a completely synthetic compound. HMG-
CoA reductase catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic cholesterol 
biosynthesis. Inhibition of the enzyme decreases de novo cholesterol synthesis, increasing 
expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This 
increases LDL uptake by the hepatocytes, decreasing the amount of LDL-cholesterol in 
the blood. Like other statins, atorvastatin also reduces blood levels of triglycerides and 
slightly increases levels of HDL-cholesterol. 
Pharmacokinetics: 
Bioavailability     : 12% 
Metabolism          : Hepatic - CYP3A4 
Half-life       : 14hrs 
Excretion             : Bile 
Drug Interactions: Interactions with clofibrate, fenofibrate, gemfibrozil, which are 
fibrates used in accessory therapy in many forms of hypercholesterolemia, usually in 
combination with statins, increase the risk of myopathy and rhabdomyolysis. 
Contraindications: Active liver disease: cholestasis, hepatic encephalopathy, hepatitis, 
and Jaundice. 
 Unexplained elevations in AST or ALT levels 
 Pregnancy 
 Breastfeeding 
Adverse Reactions: 
 Myopathy 
 Rhabdomyolysis  
 Headache  
 Weakness 
 Insomnia and dizziness 
 Chest pain and peripheral edema 
 Abdominal pain. 
 Back pain 
 Rheumatoid arthritis 
  
 
6. EXCIPIENT PROFILE
30, 31 
  
 Pharmaceutical excipients are compounds other than the pharmacologically active 
drug or prodrug, which are included in the manufacturing process or  contained in the 
finished pharmaceutical product dosage form. Excipients provide enhanced functionality 
to  the pharmaceuticals  aid  the innovations in the drug  development  and  help  improve 
patient  life  as  well.  Excipients  make  the  products  more  functional  at  a  lower  cost,  
a benefit much desired by the pharmaceutical industry  that is inundated with pressures to 
reduce costs. 
Excipients play a wide variety of functional roles in pharmaceutical dosage forms 
including: 
 Modulating the solubility and bioavailability of active pharmaceutical ingredients 
(APIs). 
 Increasing the stability of active ingredients in dosage forms. 
 Helping active ingredients maintain preferred polymorphic forms or 
conformations. 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 Acting as antioxidants, emulsifying agents, aerosol propellants, tablet binders, and 
tablet disintegrates. 
 Preventing  aggregation  or  dissociation  (e.g.,  of  protein  and  polysaccharide 
actives) 
 Modulating immunogenic responses of active ingredients (e.g., adjutants). 
 
 
 
 
 
 
 
 
 
 
 
  
 
1) SODIUM STARCH GLYCOLATE 
 
Non Proprietary Names 
BP: Sodium Starch Glycolate 
PhEur: Sodium Starch Glycolate 
USP-NF: Sodium Starch Glycolate 
Synonyms : Carboxymethyl starch, sodium salt; Explosol; Explotab;Glycolys; Primojel; 
starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
Description: Sodium starch glycolate is a white to off-white, odorless, tasteless, free-
flowing powder. 
The PhEur 2005 states that it consists of oval /spherical granules,30–100mm. Spherical 
granules ranging from 10–35 mm in diameter. 
Chemical Name: Sodium carboxymethyl starch  
MolecularWeight: 5, 00,000-10, 00,000. 
 
Structural Formula: 
 
 
 
 
 
 
 
 
Functional Category : Tablet and capsule disintegrant 
Safety: Sodium starch glycolate is widely used in oral pharmaceutical formulations and is 
generally regarded as a nontoxic and nonirritant material. However, oral ingestion of 
large quantities may be harmful. 
Incompatibilities: Sodium starch glycolate is incompatible with ascorbic acid. 
Typical Properties:  
Acidity/alkalinity: pH = 3.0–5.0 or pH = 5.5–7.5 for a   3.3%w/v aqueous dispersion. 
Applications in Pharmaceutical Formulation: 
  
 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulation. 
 It is commonly used in tablets prepared by either direct compression or wet-
granulation Increasing the tablet compression pressure also appears to have no effect on 
disintegration time. 
 Sodium starch glycolate has also been investigated for use as a suspending vehicle 
 
2) MICRO CRYSTALLINE CELLULOSE 
 
Synonyms: 
Avicel, Cellets, Celex, cellulose gel, hellulosum,  Microcristallinum, Celphere, Ceolus 
KG, crystalline cellulose, E460, Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, 
Vivapur. 
Chemical name: cellulose, 
Empirical formula: (C6H10O5)n. 
Description: 
Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder. 
 
Structural Formula:  
 
 
Solubility:  
Insoluble in water, dilute acids and most organic solvents, slightly soluble in 5% w/v 
NaOH solution.  
Functional categories: 
Adsorbent, suspending agent and/or viscosity increasing agent, Tablet and capsule diluent,  
Density (Bulk):       0.28 g / cm
3 
Density (Tapped):  0.43 g / cm
3 
pH:                            5.0–7.0 
Loss on drying:      Not more than 6% 
  
 
Applications: 
 Microcrystalline cellulose is used as a binder, diluent in oral tablet and capsule 
formulations. 
 Microcrystalline cellulose also has lubricant and disintegrant properties 
Stability and storage conditions: 
Microcrystalline cellulose is hygroscopic material. Stored in well closed container and 
protect from moisture. 
3) CROSCARMELLOSE SODIUM 
 
Synonyms: 
 Ac-Di-Sol carmellosum natricum conexum, cross linked carboxymethylcellulose 
Sodium, Explocel, modified cellulose gum,  Pharmacel XL Primellose, Solutab, Vivasol. 
Description: 
 Croscarmellose sodium occurs as an odorless, white or grayish white powder. 
Structural Formula:  
 
Solubility  : Practically insoluble in water, acetone, ethanol and toluene. 
Functional category  : Tablet and capsule disintegrant. 
Density (Bulk) : 0.529 g / cm
3
 
Density (Tapped) : 0.819 g / cm
3 
pH   : 5.0–7.0 in aqueous dispersions 
Loss on drying : ≤ 10.0% 
Applications             :Croscarmellose sodium is used as a disintegrant in capsules,      
                                      tablets and granules.  
Stability and storage conditions: 
 Croscarmellose sodium is a stable and hygroscopic material. Croscarmellose 
sodium should be stored in a well-closed container in a cool, dry place 
 
 
  
 
 
4) MAGNESIUM STEARATE 
 
Non proprietary names:  
BP: Magnesium stearate 
JP: Magnesium stearate 
PhEur: Magnesii stearas 
USPNF: Magnesium stearate 
Synonyms: Metallic stearic, Magnesium salt. 
Chemical name:  octadecanoic acid magnesium salt. 
Empherical formula: C36H70MgO4 
Description: 
                 It is a fine, white, precipitated or milled, impalpable powder of low bulk 
density, having a faint characteristic odor and taste. The powder is greasy to touch and 
readily adheres to the skin. 
Structural Formula:  
 
Solubility:  
Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in benzene 
and warm ethanol (95%). 
Functional category: Tablet and capsule lubricant. 
Density (Bulk):         0.159 g / cm
3 
Density (Tapped):    0.286 g / cm
3 
Loss on drying:        ≤ 6.0% 
Applications:- 
1. Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. 
2. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. 
3. It is also used in barrier creams. 
Stability and storage conditions: 
  
 
Stable, non-self polymerizable. Store in a cool, dry place in a well closed container. 
5)TALC: 
Synonyms:  
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Luzenac Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; Magsil Star; 
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore. 
Chemical Name: Talc 
Empirical formula: Mg6(Si2O5)4 
Functional Category:  
Anti-caking agent;glidant; diluent andlubricant. 
Description:   
Talc is a very fine, white to greyish-white, odourless, impalpable, unctuous, crystalline 
powder.  
Typical Properties:  
Specific gravity: 2.7–2.8 
Specific surface area: 2.41–2.42 m2/g 
Solubility:  
It is practically insoluble in dilute acids, alkalis, organic solvents and water. 
Applications:  
Talc is widely used in oral solid dosage formulations as a lubricant and diluents. It is 
widely used as a dissolution retardant in the development of controlled-release products. 
It is also used as an adsorbant. In topical preparations, talc is used as a dusting powder. 
Talc is additionally used to clarify liquids and is also used in cosmetics and food 
products. 
Stability and Storage Conditions:  
Talc is a stable material and may be sterilized by heating at 160
o
C for not less than 1 
hour. Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: It is incompatible with quaternary ammonium compounds. 
Safety: Talc is regarded as an essentially nontoxic material. Inhalation of talc causes 
irritation and may cause severe respiratory distress in infants
44
. 
 
 
 
 
  
 
6) STARCH 
 
Synonyms   : Amido; amidon; amilo; amylum 
Chemical Name  : Starch[9005-25-8]  
Empirical Formula : C6H10O5 
Functional Category :           Diluent, disintegrant, binder,  
Description: 
            Starch occurs as an odorless and tasteless, fine, white to off White powder. It 
consists of very small spherical or ovoid granules or grains whose size and shape are 
characteristic for each botanical variety. 
Applications: Starch is a versatile excipient used primarily in oral solid-dosage 
formulations where it is utilized as a binder, diluent,and disintegrant. As a diluent, starch 
is used for the preparation of standardized triturates of colorants, potent drugs, and herbal 
extracts, facilitating subsequent mixing or blending processes in manufacturing 
operations. Starch is also used in dry-filled capsule formulations for volume adjustment of 
the fill matrix,and to improve powder flow, especially when using dried starches. Starch 
acts as an antiadherent and lubricant in tableting and capsule filling. In tablet 
formulations, freshly prepared starch paste used as a binder for wet granulation. Starch is 
one of the most commonly used tablet disintegrants. 
 
  
 
 
 
 
                         
                      
 
 
 
 
 
 
  
 
7. MATERIALS AND METHOD 
 
MATERIALS: Materials used in the formulation and evaluation are listed below. 
Distilled water was used in the present study. 
 
S. No Materials Source 
 Drug   
1 Atorvastatin calcium Lara drugs , Hyderabad 
 Excipients   
2 Sodiumstarch glycolate (SSG) Lara drugs , Hyderabad 
3 
MicroCrystalline Cellulose 
(MCC) 
Lara drugs , Hyderabad 
4 Talc Lara drugs , Hyderabad 
5 Magnesium stearate Lara drugs , Hyderabad 
6 Croscarmellose Sodium Lara drugs , Hyderabad 
7 Starch Lara drugs , Hyderabad 
 
Table:6 List of materials used in formulation development 
 
 
 
 
  
 
7.1 EQUIPMENTS 
The following equipment has been used in the formulation development of 
atorvastatin calcium. 
SL.No Instruments / Equipment  Manufacturer/ supplier 
1 Analytical Weighing Balance Sartorius  
2 Humidity chamber Sigma instruments , Mumbai 
3 Tapped Density Equipment Lab india 
4 Hardness Tester Campbell Electronics 
5 Friabilator Lab india, friabilator tester, FT 1020 
6 Disintegration Apparatus Lab india 
7 Dissolution Apparatus Lab India, dissolution tester DISSO 14000 
8 Compression Machine Cadmach, Ahmedabad 
9 UV-Visible Spectrophotometer Shimadzu Corporation,Japan 
10 FTIR Shimadzu Corporation,Japan 
11 HPLC Water’s 
Table:7 List of Equipments used in Formulation Development 
 
 
 
 
 
 
 
 
 
 
  
 
FT-IR SPECTROSCOPY 
              Drug and excipients compatilibility study is done by the fourier transform 
infrared (FT-IR) spectra were obtained by using FT-IR spectroscopy. The compatibility 
studies provide the frame work for the drugs combination with the excipients in the 
fabrication of the dosage form. The study was carried out to establish that the 
therapuetically has not undergone any changes , after it has been subjected to processing 
steps during formulation of tablets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
FIG3: FT-IR SPECTRA OF ATORVASTATIN CALCIUM  PURE  DRUG 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
FIG:4:   FTIR  SPECTRA OF ATROVASTATIN CALCIUM + CROSCARMELLOSE 
SODIUM 
 
 
 
 
 
 
 
 
  
 
 
 
FIG 5:  FTIR SPECTRA OF ATORVASTATIN CALCIUM + MICRO CRYSTALLINE 
CELLULOSE: 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
FIG 6:FTIR SPECTRA OF ATORVASTATIN CALCIUM + SODIUM STARCH 
GLYCOLLATE: 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
FIG 7: FTIR SPECTRA OF ATORVASTATIN CALCIUM +  MAGNESIUM 
STEARATE: 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 METHOD OF FORMULATION 
 
Preparation of immediate release Atorvastatin calcium tablets: 
           A schematic representation of the preparation procedure of the granules is illustrate 
in Fig.:8 
 
                          Intragranular portion (weighing)     Binder solution 
 
                                Granulation (wet granules) 
 
                                        Drying at 45 degrees in tray drier 
 
Dry screening (#22) 
 
Granules (here measure % yield, bulk density, tapped density, Hausner ratio, particle size 
analysis, angle of repose) 
 
                                                Extra granular portion (#30) 
 
  Lubrication (here measure bulk density, tapped density, compressibility index, Hausner 
ratio, angle of repose) 
Compression. 
 
 
 
  
 
Table 8: Composition of Immediate Release Atorvastatin Calcium tablets  
.  
 
 
 
 
 
 
 
 
 
S.No Ingridients F1 F2 F3 F4 F5 
1 Atorvastatin calcium(API) 80 80 80 80 80 
2 Microcrystalline Cellulose 70 60 50 40 30 
3 Sodium starch glycolate 70 80 90 100 110 
4 Croscarmellose sodium 10 10 10 10 10 
5 Talc 5 5 5 5 5 
6 Magnesium stearate 5 5 5 5 5 
7 Starch 10 10 10 10 10 
  
 
                                     8. RESULTS AND DISCUSSION 
Preformulation studies of pure drug. 
S.No. Characteristics Results 
1. Organoleptic Evaluation White to off-white crystalline powder. 
2. Solubility Analysis 
Atorvastatin calcium is very slightly soluble in 
distilled water, pH 6.8 phosphate buffer, and 
acetonitrile; 
Slightly soluble in ethanol. 
Freely soluble in methanol. 
3. Bulk density                             0.5212 gm/ml 
4. Tap density 0.7678 gm/ml 
5. Compressibility index 32.16 % 
6. Hausner’s ratio 01.473 
7. Molecular weight 
1209.42 
                                                   
TABLE 9:  Preformulation studies of pure drug. 
 
Characterization of the pure drug ( API : Atorvastatin calcium) was carried out and the 
preformulation parameters were found to be within the limits. 
 
 
           
 
 
  
 
      COMPATIBILITY STUDY 
 
TABLE 10:  COMPATABILITY STUDY  
S.no 
Name of the 
Excipient 
Ratio 
API:Exp 
Initial 
Observati
on 
Final 
observation 
 
  Compati     
bility    40°C/75% RH 
2
nd
 
week 
4
th
 week 
1 
Atorvastatin Calcium 
(API) 
--- 
White to 
yellowish 
white 
White 
to 
yellow 
white 
White to 
yellow 
white 
Yes 
2 API + MCC  1 : 1 Off-white 
Off-
white 
Off-
white 
Yes 
3 API+SSG  
1 : 1 
 
White White White Yes 
4 API + Mg. Stearate 
1 : 0.05 
 
White White White Yes 
5 
API + Cross 
carmellose sodium 
1 : 0.5 
 
White White White Yes 
 
Discussion: 
Drug is mixed with excipients in different ratio. These mixtures were kept in a 5ml glass 
white colored vials and packed properly. These vials are exposed to 1) room temperature 
2) 2 – 8° C and 3) 40˚c / 75%RH. 15gm of blend is prepared which is filled in 3 vials. 
Observations for physical appearance are made at zero weeks, 2 week, and 4week, the 
samples were withdrawn for analysis. The drug-excipient interaction study was carried out 
by physical observation. Furthermore, no physical interaction with the active pharmaceutical 
ingredient was observed. 
  
 
PRE COMPRESSION PARAMETERS: 
TABLE: 11 Precompression parameters of Atorvastatin Calcium immediate release 
tablets from formulations F1 to F5: 
Formulation 
code 
Bulk 
Density 
g/ml 
Tapped 
Density g/ml 
Angle of 
repose 
Carr’s 
index % 
Hausner’s 
Ratio 
F1 0.382±0.03 0.420±0.02  
24.3 
9.13±0.68 1.10±0.05 
F2 0.375±0.04 0.411±0.04 25.6 8.88±0.37 1.09±0.03 
F3 0.384±0.02 0.4232±0.03 22.8 9.121±0.32 1.08±0.04 
F4 0.389±0.03 0.427±0.04 22.3 8.929±0.26 1.09±0.05 
F5 0.395±0.04 0.433±0.02 23.7 8.6956±0.18 1.09±0.02 
           
DISCUSSION: 
Pre-compression parameters like- bulk density, tapped density, carr’s index, Hausner’s ratio 
and angle of repose were evaluated for the formulations F1 to F5, and they were found to be 
as follows, 
1. Bulk Density:- Bulk density of all the formulations from F1 to F5 was in the range of 
0.38- 0.39 g/ml and is found to be within the limits. 
2. Tapped Density:- Tapped density of all the formulations varied from 0.42 -0.43 g/ml.  
All the above results were found to be satisfactory. 
3. Carr’s Index:- Based on the results obtained we can conclude that Formulations shows 
excellent flow.  
4. Hausner’s Ratio:-  
All the formulation shows free flow.  
5. Angle of Repose:-  
Based on angle of repose it was observed that F1to F5 showed good flow properties. 
 
  
 
TABLE: 12 COMPARISION OF BULK DENSITY OF DIFFERENT 
FORMULATIONS (F1-F5) 
S.No Formulation code Bulk Density g/ml 
1 F1 0.382±0.03 
2 F2 0.375±0.04 
3 F3 0.384±0.02 
4 F4 0.389±0.03 
5 F5 0.395±0.04 
 
 
FIG9: COMPARISION OF BULK DENSITY OF DIFFERENT 
FORMULATIONS(F1-F5) 
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TABLE 13: COMPARISION OF TAPPED DENSITY OF DIFFERENT 
FORMULATIONS (F1-F5) 
 
S.NO FORMULATIONS Tapped Density g/ml 
1 F1 0.420±0.02 
2 F2 0.411±0.04 
3 F3 0.423±0.03 
4 F4 0.427±0.04 
5 F5 0.433±0.02 
 
 
 
FIG10: COMPARISION OF TAPPED DENSITY OF DIFFERENT 
FORMULATIONS (F1-F5) 
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TABLE 14: COMPARISION OF ANGLE OF REPOSE OF DIFFERENT 
FORMULATIONS (F1-F5) 
1 F1 24.3 
2 F2 25.6 
3 F3 22.8 
4 F4 22.3 
5 F5 23.7 
 
 
                  
FIG11: COMPARISION OF ANGLE OF REPOSE OF DIFFERENT 
FORMULATIONS 
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TABLE15: COMPARISION OF COMPRESSIBILITY INDEX OF DIFFERENT 
FORMULATIONS (F1-F5) 
S.NO Formulation code Carr’s index % 
1 F1 9.13±0.68 
2 F2 8.88±0.37 
3 F3 9.12±0.32 
4 F4 8.92±26 
5 F5 8.69±0.18 
 
 
 
FIG12: COMPARISION OF COMPRESSIBILITY INDEX OF DIFFERENT 
FORMULATIONS (F1-F5) 
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TABLE16: COMPARISION OF HAUSNER’S RATIO OF DIFFERENT 
FORMULATIONS (F1-F5) 
S.NO Formulation 
code 
Hausner’s 
Ratio 
01 F1 1.10±0.05 
2 F2 1.09±0.03 
3 F3 1.08±0.04 
4 F4 1.09±0.05 
5 F5 1.09±0.02 
 
 
FIG13: COMPARISION OF HAUSNER’S RATIO OF DIFFERENT 
FORMULATIONS (F1-F5) 
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  TABLE 17:  POST COMPRESSION PARAMETERS  
Formulation 
code 
Hardness 
(kg/cm
2
) 
Friability (%) Avg weight 
(mg) 
Thickness 
(mm) 
F1 2.2±0.15 0.32±0.036 251±0.13 3.2±0.014 
F2 2.6±0.17 0.38±0.041 250±0.16 3.2±0.011 
F3 2.6±0.21 0.28±0.026 255±0.17 3.3±0.016 
F4 2.5±0.19 0.48±0.028 253±0.12 3.2±0.017 
F5 2.8±0.14 0.37±0.031 251±0.16 3.0±0.015 
 
 
DISCUSSION: 
 
1. Hardness:-  
The formulations showed hardness in the range of 2.2 to 2.8kg/cm
2
 which was 
acceptable.  
 
2. Friability:-  
The percentage friability of tablet was ranging 0.3% - 0.4% which was less than the 
standard limit of 1% indicates that the prepared tablets are mechanically stable 
 
3. Weight Variation:-  
Tablet weight was ranging 250-255 mg for core tablets (Target wt – 250 mg/tablet) 
which is less than 5% indicates that the variation in the weight of the tablets is within 
standard official limits. No weight variation was observed, as the blend characteristics were 
maintained through the development process 
 
4. Thickness:-  
Most of the formulations showed a range of thickness of 3.0 to 3.3mm.  
 
  
 
 
TABLE 18:  COMPARISION OF HARDNESS OF DIFFERENT       
FORMULATIONS (F1-F5)  
S.NO Formulation code Hardness (kg/cm
2
) 
1 F1 2.2±0.15 
2 F2 2.6±0.17 
3 F3 2.6±0.21 
4 F4 2.5±0.19 
5 F5 2.8±0.14 
 
 
 
FIG14:COMPARISON OF HARDNESS OF DIFFERENT FORMULATIONS     
(F1-F5) 
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TABLE19:  COMPARISION OF FRIABILITY OF DIFFERENT 
FORMULATIONS (F1-F5) 
S.NO Formulation code Friability (%) 
1 F1 0.32±0.36 
2 F2 0.38±0.41 
3 F3 0.28±0.026 
4 F4 0.48±0.028 
5 F5 0.37±0.031 
 
 
 
 
FIG15: COMPARISION OF FRIABILITY OF DIFFERENT FORMULATIONS 
(F1-F5)  
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TABLE 20 : COMPARISION OF AVERAGE WEIGHT OF  DIFFERENT 
FORMULATIONS(F1-F5) 
S.NO Formulation code Avg weight (mg) 
1 F1 251±0.13 
2 F2 250±0.17 
3 F3 255±0.21 
4 F4 253±0.19 
5 F5 251±0.16 
 
 
FIG16: COMPARISION OF AVERAGE WEIGHT OF DIFFERENT 
FORMULATIONS (F1-F5) 
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TABLE21: COMPARISION OF THICKNESS OF DIFFERENT 
FORMULATIONS (F1-F5) 
S.NO Formulation 
code 
Thickness 
(mm) 
1 F1 3.2±0.014 
2 F2 3.2±0.011 
3 F3 3.3±0.016 
4 F4 3.2±0.017 
5 F5 3.0±0.015 
 
 
 
FIG 17: COMPARISION OF THICKNESS OF DIFFERENT 
FORMULATIONS(F1-F5) 
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TABLE22:  IN-VITRO  DISSOLUTION PROFILE OF ALL THE 
FORMULATIONS       (F1-F5) 
 
Time(mins) F1 F2 F3 F4 F5 
0 0 0 0 0 0 
5 26.54 31.25 62.83 58.26 71.18 
10 36.38 42.68 74.74 63.26 86.62 
15 44.85 48.78 86.57 72.25 93.54 
30 67.57 72.27 91.98 88.64 99.68 
 
 
FIG18:  IN-VITRO DISSOLUTION PROFILE OF ALL THE 
FORMULATIONS(F1-F5) 
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TABLE 23:COMPARISION OF IN-VITRO DISSOLUTION PROFILE OF 
MARKET PRODUCT WITH FORMULATION(F5) 
 
Time(mins) F5 Marketed SAMPLE 
0 0 0 
5 71.18 69 
10 86.62 91 
15 93.54 96 
30 99.68 100 
 
 
FIG19: COMPARISION OF IN-VITRO DISSOLUTION PROFILE OF MARKET 
PRODUCT WITH FORMULATION(F5) 
 
 
 
 
    
  
 
TABLE24:  DISINTEGRATION TIME OF ATORVASTATIN CALCIUM 
TABLETS FOR DIFFERENT FORMULATIONS 
FORMULATION CODE DISNTEGRATION (MINS) 
F1 4min 11sec 
F2 3min.48sec 
F3 3min 54sec 
F4 3min 30sec 
F5 3min 20sec 
 
 
FIG20: COMPARISION OF DISINTEGRATION TIME OF ALL THE 
FORMULATIONS(F1-F5) 
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                           ASSAY OF ATORVASTATIN CALCIUM 
 
TABLE: 25  ASSAY OF ATORVASTATIN CALCIUM IMMEDIATE RELEASE 
TABLETS FOR DIFFERENT FORMULATIONS(F1-F5) 
 
 
S.NO FORMULATION 
CODE 
PERCENTAGE OF 
DRUG CONTENT 
1 F1 99.8 
2 F2 98.6 
3 F3 100.2 
4 F4 99.4 
5 F5 100.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                     STABILITY STUDIES 
                                                     
                                              TABLE:26 STABILITY STUDIES 
 
 
Stability 
condition 
 
Description 
 
Assay (%)  
(95%-105%) 
 
Dissolution study 
in 6.8 Phosphate 
buffer. 
   Room 
temperature 
 (Initial) 
White colored , round shaped, film 
coated tablets 
100.7% 99.68% 
40°C / 75% 
RH 
(1month ) 
White colored , round shaped, film 
coated tablets 
100.11% 97.81% 
40°C / 75% 
RH 
(2months) 
White colored , round shaped, film 
coated tablets 
99.64% 97.67% 
25°C/60% 
RH 
(1 month) 
White colored, round shaped, film 
coated tablets. 
99.87% 98.89% 
25°C/60% 
RH 
(2months) 
White colored, round shaped, film 
coated tablets. 
99.38% 97.85% 
  
 
ASSAY: 
Assay is an indicative of the amount of the drug present in the dosage form. Here 
it gives the insight information about the substances of the process and about effect of 
changes.    
Assay study for formulation F5 at40
0
c/75RH 
In Formulation F5 the assay of the tablets was found to be 100.7.% initially, after 1 month 
it was decreased to 100.11% and after 2month 99.64%, at 40
0
c/RH 
 
 
  
                          FIG:21 Assay study for formulation F5 at40
0
c/75RH 
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Assay formulation F5at25
0
c/60RH 
 
In Formulation F5 the assay of the tablets was found to be 100.7. % initially, after 1 
month it was decreased to 99.87% and after 2month 99.38%, at 25
0
c/60RH 
 
 
 
                              FIG:22 Assay formulation F5 at25
0
c/60RH 
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DISSOLUTION STUDIES:      
The dissolution is an indicated the amount of drug release from the dosage form. 
Here it gives the insight information about the substances of the process and about effect 
of changes. Dissolution studies are carried out in the following media. 
Acidic Stage: 
                Medium          :  6.8 phosphate buffer 
                Type of apparatus                           : USP -   II (paddle type) 
                RPM               : 100 
                Volume             : 900 ml 
                Temperature              : 37ºC± 0.5 
               Time                :  30min 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
In-vitro Dissolution for formulation F5 at25
0
c/60RH 
In Formulation F5 the % Drug release of the tablets was found to be 99.68% 
initially, after 1
st
 month 97.81% and after 2
nd month
 97.85%   at 25
0
C/60%RH 
 
 
FIG 23: In-vitro Dissolution for formulation F5 at25
0
c/60RH 
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In-vitro Dissolution for formulation F5 at 40
0
c/75RH 
In Formulation F5 the % Drug release  of the tablets was found to be 99.68% 
initially, after 1
st
 month it was decreased 97.81% and  after 2
nd  
month 97.67%   at 
40
0
C/75%RH 
 
 
FIG24: In-vitro Dissolution for formulation F5 at 40
0
c/75RH 
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DISCUSSION 
In the present study, various formulations of immediate release Atorvastatin Calcium tablets 
were prepared by wet granulation process. 
UV spectrum analysis  
The UV spectrum of Atorvastatin Calcium was found to have wavelength maxima at 244 
nm, when scanned in a range of UV-spectrum from 200-380 nm.  
 
Standard Calibration Curve of Atorvastatin  Calcium at 244 nm.  
The absorbance of the standard solution of Atorvastatin Calcium determined at 5 
concentration levels ranging from 5-25μg/ml were plotted as absorbance versus respective 
concentration which gave a linear line with regression co-efficient 0.9989. The regression 
equation was found to be Y = 0.0277X + 0.0052 so it followed Beer- Lambert’s law at the 
concentration range of 5-25μg/ml.  
 
Pre compression parameters 
The results of pre compression parameters such as angle of repose, bulk density, tapped 
density, compressibility index, hausner’s ratio, of the different formulations with in the 
limits. 
 
Post compression parameters 
The results of the post compression parameters such as thickness, hardness, friability, weight 
variation for the prepared formulations with in the limits. 
 
 In-Vitro Drug Release 
Dissolution report of F1 showed that, overall drug release is so much less. It was also 
found that the disintegration time is less.  
The main variable here was MCC and SSG were equally used. F1 and F2 results were not 
satisfactory.  
In the formulations of F3 and F4 gradually increasing the super disintegrant agent SSG 
increases the cumulative percentage of drug release. 
  
 
In the finalized formulation F5 containing high amount of SSG shows maximum(99.68%) 
in-vitro drug release at the end of 30mins,which can be matched with the marketed 
product.    
STABILITY STUDIES   
The optimized formulation was scaled up in three  batches and were kept for stability 
studies. Stability studies were performed at 40
0
C/75%RH ( 2 months) and 25
0
c/60RH(2 
months) and parameters like physical parameters, percentage drug content and in-vitro 
dissolution studies were evaluated 
RH as per the ICH guidelines for one month, the drug release and content were not altered 
with the standard, so the prepared formulation was found to be stable. 
FT-IR SPECTRAL ANALYSIS: 
 It showed that there were no change of any characteristic peaks of pure durg Atorvastatin 
calcium and excipients which confirmed that absence of chemical interaction between 
pure drug and excipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
       9. SUMMARY AND CONCLUSION 
SUMMARY 
 The aim of the present study was to formulate and develop immediate release 
tablets of Atorvastatin calcium by addition of different diluents and disintegrants.  
 
 Atorvastatin calcium tablets were formulated  by wet granulation method by using 
starch as binding agent, MCC as diluents and it has  disintegrating agent property, 
croscaramellose as dissintegrating agent, SSC(sodium starch glycolate) as Super 
disintegrating agent, magnesium stearate as lubricant with good release profile for 
a specified period of time up to 30mins. 
 
 Compatibility studies was performed and found no interaction between drug and 
excipients. 
 
 Prior to compression, the blend of drug and excipients were evaluated for flow 
properties such as angle of repose, loose bulk density, Tapped density, % 
compressibility and Hausner’s ratio.  Good flow properties are observed in all the 
formulations. 
 
 By using wet granulation technique Atorvastatin calcium tablets are prepared. 
 
 Post compression evaluation of prepared immediate release tablets of Atorvastatin 
calcium were carried out with the help of different Pharmacopoeial and non 
pharmacopoeial (industry specified) tests. 
 
 
 The shape and colour of all the formulations were found to be round, biconvex 
shaped and white to off white in color. The thickness was found to be uniform in 
specific formulations. The hardness and friability values of all the formulated 
tablets were within the limits and found to be mechanically stable. The % weight 
variation were carried out for all the formulations and found to be within the 
Pharmacopoeial limits 
 
  
 
 The invitro disintegration time for all the formulations is below 4 minutes. All 
formulations were subjected for dissolution studies. All formulations of 
Atorvastatin calcium have shown drug release within 30 min. 
 
 Finally, formulation F5 was selected as best formulation as it showed the 
dissolution profile similar to that of innovator product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CONCLUSION 
 In-vitro release profile of tablets of all trials was satisfactory and drug release was 
achieved within 30 minutes 
 Success of the In vitro drug release studies recommends the product for further in 
vivo studies, which may improve patient compliance  
 From  the  literature  Atorvastatin calcium,  individual  dosage  form  was used  in  
the  management  of  hyperlipidemia. Immediate release layer imparts rapid onset 
of action and regulates the body cholesterol. 
 From the results formulation F -5 has been selected as best formulation among all 
the other formulations. Formulation F – 5 provides better in vitro release. 
 The  formula  optimized  and  it  was  selected  for  stability  studies  as  per  ICH 
guidelines and the formulation was found to be stable. Stability studies were 
conducted for F5 for 1
st
 & 2
nd
 month, which were found to be stable and concluded 
that formulation F5 was better stable product with good quality.  
 Among the 5 formulation designed F5 formulation was considered to be the 
best formulation as it showed a similar dissolution profile similar to that of 
the innovator product LIPITOR. 
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